Novartis will acquire a clinical-stage molecular glue named MRT-6160, providing Monte Rosa with an upfront payment of $150 million.

According to statistical data, the miRNA drug market was estimated at approximately $160.5 million in 2017, with an expected compound annual growth rate (CAGR) of 18.6%.

As a cutting-edge therapeutic approach, antisense oligonucleotide drugs precisely target the mRNA or pre-mRNA of disease-causing genes.

Otsuka Pharmaceutical announced positive top-line interim data from the phase III clinical trial of sibeprenlimab for treating adults with IgA nephropathy.

Hope Medicine (HopeMed) announced positive interim results from a Phase 2 study of HMI-115 in women with moderate to severe endometriosis-associated pain.

Tonix Pharmaceuticals announced that it has submitted a New Drug Application (NDA) to the U.S. FDA for TNX-102 SL (Cyclobenzaprine hydrochloride).

Longboard Pharmaceuticals has recently announced the initiation of the global Phase 3 DEEp SEA study.

Novo Nordisk announced on its official website the primary results of a Phase 2a clinical trial for its investigational drug monlunabant (previously known as INV-202).

Sanofi announced its entry into the nuclear medicine field through an exclusive licensing agreement with RadioMedix and Orano Med to jointly develop next-generation RLT for rare cancers.

AstraZeneca submitted a market application for the injectable drug Tremelimumab.

Nurix Therapeutics unveiled promising data from its Phase 1a/1b clinical trial of NX-5948 at the 12th International Workshop on Waldenstrom's Macroglobulinemia.

In the development of antibody-drug conjugates (ADCs), selecting an appropriate linker is a critical factor that determines the efficacy and safety of the final product.